Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioma 2Glioblastoma 2Cholangiocarcinoma 2Spinal Cord Neoplasms 1Oligodendroglioma 1Neoplasms 1Leukemia, Myeloid, Acute 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Bile Duct Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 74Radiotherapy 34Carboplatin 21Bevacizumab 18Magnetic Resonance Spectroscopy 17Irinotecan 16Carmustine 16Vincristine 14Surgical Procedures, Operative 13Filgrastim 13Procarbazine 10Erlotinib Hydrochloride 8Cyclophosphamide 8Peripheral Blood Stem Cell Transplantation 7O(6)-benzylguanine 7Lomustine 7Etoposide 7sargramostim 6Imatinib Mesylate 6Flucytosine 6Cisplatin 62-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 6temsirolimus 5Vorinostat 5Thiotepa 5Radiotherapy, Intensity-Modulated 5Radiation 5Immunohistochemistry 5Biopsy 52,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Oligodendroglioma × olutasidenib × CNS × Clear all
NCT06161974 2025-02-21

Study of Olutasidenib and Temozolomide in HGG

Rigel Pharmaceuticals

Phase 2 Recruiting
60 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡